{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:05Z","timestamp":1792785065601,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Physician-Scientist Programme of Heidelberg University, Faculty of Medicine"},{"name":"\u201cThe Skin as Sensor and Effector Organ Orchestrating Local and Systemic Immunity\u201d","award":["TRR156\/2 \u2013 246807620"],"award-info":[{"award-number":["TRR156\/2 \u2013 246807620"]}]},{"name":"\u201cThe Skin as Sensor and Effector Organ Orchestrating Local and Systemic Immunity\u201d, DFG","award":["TRR156\/2 \u2013 246807620"],"award-info":[{"award-number":["TRR156\/2 \u2013 246807620"]}]},{"name":"Boehringer Ingelheim Foundation \u201cNovel and neglected cardiovascular risk factors: molecular mechanisms and therapeutic implications\u201d","id":[{"id":"https:\/\/ror.org\/03tx8dq56","id-type":"ROR","asserted-by":"crossref"}]},{"name":"SFB: (\u201cThe Skin as Sensor and Effector Organ Orchestrating Local and Systemic Immunity\u201d DFG","award":["TRR156\/2 \u2013 246807620"],"award-info":[{"award-number":["TRR156\/2 \u2013 246807620"]}]},{"DOI":"10.13039\/501100005971","name":"Deutsche Herzstiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DZHK Excellence Programme"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune-mediated diseases, including moderate-to-severe psoriasis, represent an independent risk factor for cardiovascular disease (CVD) development. Although patients with these conditions require a specific approach to cardiovascular prevention, structures equipped for this task still do not exist. We therefore investigated preventive screening in a specialized cardiology outpatient clinic in this high-risk patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Within a pilot study, we report on a cohort of patients from the psoriasis outpatient clinic (Department of Dermatology, University Medical Center, Mainz, Germany) investigated in a specialized consultation at the Department of Cardiology (University Medical Center, Mainz, Germany). Examination consisted of classical cardiological medical history, cardiological instrumental diagnostics (12-lead ECG, 24-h ECG, 24-h blood pressure profile, transthoracic echocardiography) and lipid profile. Psoriasis severity was categorized by Psoriasis Area and Severity (PASI) score and estimated cardiovascular prognosis was calculated by established risk scores. PASI score was correlated to calculated cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 20 patients examined (median (IQR) age 43 (36\u201363) years; 70% men), all demonstrated at least one other established cardiovascular risk factor (CVRF) in addition to psoriasis. The median estimated cardiovascular prognosis calculated as 10-year risk of fatal and non-fatal cardiovascular events (myocardial infarction, stroke) was 3% (2\u20136) and 2% (1\u20137) applying the score by the Systematic Coronary Risk Estimation 2 (SCORE2) and Predicting Risk of cardiovascular disease EVENTs (PREVENT\u2122) score, respectively. 60% of patients demonstrated at least two classical CVRF. Most pronounced was overweight\/obesity (90%; median BMI 29 (26\u201336) kg\/m2), followed by arterial hypertension (40%; median 24-h systolic to diastolic blood pressure 120 (115\u2013124) mmHg to 70 (67\u201379) mmHg), and dyslipidemia (25%). Elevated LDL cholesterol (&gt;\u200970 mg\/dl) and Lp(a) (&gt;\u200930 mg\/dl) were observed in 85% and 25% of patients, respectively. Echocardiography and 24-h ECG revealed no significant abnormalities in most of the patients. The current PASI score of the patients did not relate to the calculated cardiovascular risk. Importantly, including the cardiovascular risk factor of psoriasis itself in the estimation of the cardiological prognosis is unavailable in established risk scores. Recommended life-style changes or changes in medication concerned dyslipidemia as well as blood pressure regulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psoriasis patients are at increased risk for CVD and demonstrate an unmet need for preventive cardiovascular investigation. Optimizing lipid diagnostics and blood pressure may be beneficial in this high-risk patient cohort. Our hypothesis-generating study supports routine CVRF screening by dermatologists and primary care physicians to identify the overall cardiovascular risk profile, and interdisciplinary specialized care for specific cardiological challenges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41598-026-72219-1","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:53:47Z","timestamp":1791042827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A specialized cardiological outpatient clinic for patients with psoriasis: results from a single-center pilot study"],"prefix":"10.1038","volume":"16","author":[{"given":"Lena","family":"Schnauder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-2658","authenticated-orcid":false,"given":"Katharina S.","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Schulzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bombace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Koppe-Schmei\u00dfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Staubach-Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1446-8101","authenticated-orcid":false,"given":"Johannes","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4462-3747","authenticated-orcid":false,"given":"Susanne Helena","family":"Karbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"2","key":"72219_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/annrheumdis-2018-214065","volume":"78","author":"P Sewerin","year":"2019","unstructured":"Sewerin, P., Brinks, R., Schneider, M., Haase, I. & Vordenbaumen, S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 78 (2), 286\u2013287 (2019).","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"72219_CR2","first-page":"718","volume":"21","author":"KS Kommoss","year":"2023","unstructured":"Kommoss, K. S. et al. Cardiovascular comorbidity in psoriasis - Psoriatic inflammation is more than just skin deep. J. Dtsch. Dermatol. Ges. 21 (7), 718\u2013725 (2023).","journal-title":"J. Dtsch. Dermatol. Ges"},{"issue":"8","key":"72219_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","volume":"31","author":"NN Mehta","year":"2010","unstructured":"Mehta, N. N. et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur. Heart J. 31 (8), 1000\u20131006 (2010).","journal-title":"Eur. Heart J."},{"issue":"14","key":"72219_CR4","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand, J. M. et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (14), 1735\u20131741 (2006).","journal-title":"JAMA"},{"issue":"10","key":"72219_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1038\/jid.2013.149","volume":"133","author":"EJ Samarasekera","year":"2013","unstructured":"Samarasekera, E. J., Neilson, J. M., Warren, R. B., Parnham, J. & Smith, C. H. Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis. J. Invest. Dermatol. 133 (10), 2340\u20132346 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"72219_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/VHRM.S464471","volume":"20","author":"H Mehta","year":"2024","unstructured":"Boehncke, W. H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: Causes and consequences. Front. Immunol. 9, 579 (2018).","journal-title":"Vasc. Health Risk Manag."},{"issue":"12","key":"72219_CR7","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","volume":"34","author":"S Karbach","year":"2014","unstructured":"Mehta, H. et al. Cardiovascular considerations and implications for treatment in psoriasis: An updated review. Vasc. Health Risk Manag. 20, 215\u2013229 (2024).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"72219_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Karbach, S. et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler. Thromb. Vasc. Biol. 34 (12), 2658\u20132668 (2014).","journal-title":"Front. Immunol."},{"key":"72219_CR9","doi-asserted-by":"crossref","unstructured":"Ponikowska, M. et al. Cardiovascular disease and psoriasis. Dermatol. Ther. (Heidelb). (2025).","DOI":"10.1007\/s13555-025-01566-0"},{"issue":"6","key":"72219_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino","year":"2008","unstructured":"D\u2019Agostino, R. B. et al. Generalcardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 117 (6), 743\u2013753 (2008).","journal-title":"Circulation"},{"issue":"3","key":"72219_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita, J. et al. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol. 76 (3), 377\u2013390 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"72219_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","volume":"149","author":"P Jensen","year":"2013","unstructured":"Jensen, P. et al. Effect of weight loss on the severity of psoriasis: A randomized clinical study. JAMA Dermatol. 149 (7), 795\u2013801 (2013).","journal-title":"JAMA Dermatol."},{"issue":"3","key":"72219_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2017.04.015","volume":"77","author":"EJ Lee","year":"2017","unstructured":"Lee, E. J., Han, K. D., Han, J. H. & Lee, J. H. Smoking and risk of psoriasis: A nationwide cohort study. J. Am. Acad. Dermatol. 77 (3), 573\u2013575 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"72219_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/bjd.12101","volume":"168","author":"C Ma","year":"2013","unstructured":"Ma, C., Harskamp, C. T., Armstrong, E. J. & Armstrong, A. W. The association between psoriasis and dyslipidaemia: A systematic review. Br. J. Dermatol. 168 (3), 486\u2013495 (2013).","journal-title":"Br. J. Dermatol."},{"issue":"33","key":"72219_CR15","doi-asserted-by":"publisher","first-page":"112045","DOI":"10.12998\/wjcc.v13.i33.112045","volume":"13","author":"MR Fragkouli","year":"2025","unstructured":"Fragkouli, M. R. et al. Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis. World J. Clin. Cases. 13 (33), 112045 (2025).","journal-title":"World J. Clin. Cases"},{"issue":"6","key":"72219_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.5114\/ada.2019.91420","volume":"36","author":"M Ramezani","year":"2019","unstructured":"Ramezani, M., Zavattaro, E. & Sadeghi, M. Evaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: A systematic review and meta-analysis of case-control studies. Postepy Dermatol. Alergol. 36 (6), 692\u2013702 (2019).","journal-title":"Postepy Dermatol. Alergol."},{"issue":"4","key":"72219_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets, C. A. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J. Am. Acad. Dermatol. 80 (4), 1073\u20131113 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"72219_CR18","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/jdv.15177","volume":"32","author":"E Dauden","year":"2018","unstructured":"Dauden, E. et al. Position statement for the management of comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol. 32 (12), 2058\u20132073 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"72219_CR19","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/jdv.12024","volume":"27","author":"E Dauden","year":"2013","unstructured":"Dauden, E. et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 27 (11), 1387\u20131404 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"72219_CR20","first-page":"e563","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett, D. K. et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140 (11), e563\u2013e95 (2019).","journal-title":"Circulation"},{"issue":"9","key":"72219_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2011.119","volume":"147","author":"NN Mehta","year":"2011","unstructured":"Mehta, N. N. et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET\/CT): A pilot study. Arch. Dermatol. 147 (9), 1031\u20131039 (2011).","journal-title":"Arch. Dermatol."},{"key":"72219_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2021.11.008","volume":"339","author":"NH Patel","year":"2021","unstructured":"Patel, N. H. et al. Heightened splenic and bone marrow uptake of (18)F-FDG PET\/CT is associated with systemic inflammation and subclinical atherosclerosis by CCTA in psoriasis: An observational study. Atherosclerosis 339, 20\u201326 (2021).","journal-title":"Atherosclerosis"},{"issue":"9","key":"72219_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","volume":"4","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi, Y. A. et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol. 4 (9), 885\u2013891 (2019).","journal-title":"JAMA Cardiol."},{"issue":"4","key":"72219_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2020.10.094","volume":"84","author":"YA Elnabawi","year":"2021","unstructured":"Elnabawi, Y. A. et al. CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. J. Am. Acad. Dermatol. 84 (4), 913\u2013920 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"72219_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/10715762.2019.1648800","volume":"53","author":"SP Cannavo","year":"2019","unstructured":"Cannavo, S. P., Riso, G., Casciaro, M., Di Salvo, E. & Gangemi, S. Oxidative stress involvement in psoriasis: A systematic review. Free Radic. Res. 53 (8), 829\u2013840 (2019).","journal-title":"Free Radic. Res."},{"issue":"19","key":"72219_CR26","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","volume":"87","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal, R. S. et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of dyslipidemia: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 87 (19), 2624\u20132757 (2026).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"72219_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach, F. et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 41 (1), 111\u2013188 (2019).","journal-title":"Eur. Heart J."},{"issue":"38","key":"72219_CR28","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy, J. W. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 45 (38), 3912\u20134018 (2024).","journal-title":"Eur. Heart J."},{"issue":"36","key":"72219_CR29","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder, I. C. et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 45 (36), 3314\u20133414 (2024).","journal-title":"Eur. Heart J."},{"issue":"34","key":"72219_CR30","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren, F. L. J. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42 (34), 3227\u20133337 (2021).","journal-title":"Eur. Heart J."},{"issue":"24","key":"72219_CR31","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan, S. S. et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. Circulation 148 (24), 1982\u20132004 (2023).","journal-title":"Circulation"},{"issue":"6","key":"72219_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan, S. S. et al. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation 149 (6), 430\u2013449 (2024).","journal-title":"Circulation"},{"issue":"1","key":"72219_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","volume":"29","author":"FLJ Visseren","year":"2022","unstructured":"Visseren, F. L. J. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Prev. Cardiol. 29 (1), 5\u2013115 (2022).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"72219_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of cardiovascular imaging. J. Am. Soc. Echocardiogr. 28 (1), 1\u201339e14 (2015).","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"12","key":"72219_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","volume":"17","author":"SF Nagueh","year":"2016","unstructured":"Nagueh, S. F. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 17 (12), 1321\u20131360 (2016).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"3","key":"72219_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ejhf.1741","volume":"22","author":"B Pieske","year":"2020","unstructured":"Pieske, B. et al. How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 22 (3), 391\u2013412 (2020).","journal-title":"Eur. J. Heart Fail."},{"issue":"13","key":"72219_CR37","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","volume":"77","author":"MS Garshick","year":"2021","unstructured":"Garshick, M. S., Ward, N. L., Krueger, J. G. & Berger, J. S. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J. Am. Coll. Cardiol. 77 (13), 1670\u20131680 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"72219_CR38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3899\/jrheum.170379","volume":"45","author":"L Eder","year":"2018","unstructured":"Eder, L. et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: An international multicenter study. J. Rheumatol. 45 (3), 378\u2013384 (2018).","journal-title":"J. Rheumatol."},{"issue":"1","key":"72219_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2011.06.035","volume":"67","author":"AB Kimball","year":"2012","unstructured":"Kimball, A. B. et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J. Am. Acad. Dermatol. 67 (1), 76\u201385 (2012).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"72219_CR40","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jid.2023.12.008","volume":"144","author":"WB Song","year":"2024","unstructured":"Song, W. B. et al. A care coordination model to prevent cardiovascular events in patients with psoriatic disease: A multicenter pilot study. J. Invest. Dermatol. 144 (6), 1405\u20139e1 (2024).","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"72219_CR41","doi-asserted-by":"publisher","first-page":"775e1","DOI":"10.1016\/j.amjmed.2011.03.028","volume":"124","author":"NN Mehta","year":"2011","unstructured":"Mehta, N. N. et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am. J. Med. 124 (8), 775e1\u2013775e6 (2011).","journal-title":"Am. J. Med."},{"issue":"4","key":"72219_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/eurjpc\/zwaa033","volume":"29","author":"A Gonzalez-Cantero","year":"2022","unstructured":"Gonzalez-Cantero, A. et al. Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: Results from two observational cohorts. Eur. J. Prev. Cardiol. 29 (4), 591\u2013598 (2022).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"72219_CR44","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3389\/fimmu.2019.03096","volume":"10","author":"E von Stebut","year":"2019","unstructured":"von Stebut, E. et al. IL-17A in psoriasis and beyond: Cardiovascular and metabolic implications. Front. Immunol. 10, 3096 (2019).","journal-title":"Front. Immunol."},{"issue":"3","key":"72219_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm.2627","volume":"18","author":"O Osborn","year":"2012","unstructured":"Osborn, O. & Olefsky, J. M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18 (3), 363\u2013374 (2012).","journal-title":"Nat. Med."},{"issue":"4","key":"72219_CR46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jcct.2020.12.006","volume":"15","author":"AK Dey","year":"2021","unstructured":"Dey, A. K. et al. Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study. J. Cardiovasc. Comput. Tomogr. 15 (4), 372\u2013379 (2021).","journal-title":"J. Cardiovasc. Comput. Tomogr"},{"issue":"5","key":"72219_CR47","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jaad.2022.08.027","volume":"88","author":"R O\u2019Hagan","year":"2023","unstructured":"O\u2019Hagan, R. et al. Association of the triglyceride glucose index with insulin resistance and subclinical atherosclerosis in psoriasis: An observational cohort study. J. Am. Acad. Dermatol. 88 (5), 1131\u20131134 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"72219_CR48","doi-asserted-by":"publisher","first-page":"adv5087","DOI":"10.2340\/actadv.v103.5087","volume":"103","author":"E Berna-Rico","year":"2023","unstructured":"Berna-Rico, E. et al. Cardiovascular screening practices and statin prescription habits in patients with psoriasis among dermatologists, rheumatologists and primary care physicians. Acta Derm. Venereol. 103, adv5087 (2023).","journal-title":"Acta Derm. Venereol."},{"issue":"12","key":"72219_CR49","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377 (12), 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"10384","key":"72219_CR50","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","volume":"401","author":"PM Ridker","year":"2023","unstructured":"Ridker, P. M. et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials. Lancet 401 (10384), 1293\u20131301 (2023).","journal-title":"Lancet"},{"issue":"10","key":"72219_CR51","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.jid.2025.03.014","volume":"145","author":"A Lecumberri","year":"2025","unstructured":"Lecumberri, A. et al. Residual inflammation in patients with psoriasis treated with biologic therapy: Findings from 3 prospective observational cohorts. J. Invest. Dermatol. 145 (10), 2474\u20132483.e4 (2025).","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"72219_CR52","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess, S. et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A Mendelian randomization analysis. JAMA Cardiol. 3 (7), 619\u2013627 (2018).","journal-title":"JAMA Cardiol."},{"issue":"10155","key":"72219_CR53","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit, P. et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: Individual patient-data meta-analysis of statin outcome trials. Lancet 392 (10155), 1311\u20131320 (2018).","journal-title":"Lancet"},{"issue":"4","key":"72219_CR54","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jid.2018.07.046","volume":"139","author":"C Luan","year":"2019","unstructured":"Luan, C. et al. Potentiation of psoriasis-like inflammation by PCSK9. J. Invest. Dermatol. 139 (4), 859\u2013867 (2019).","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"72219_CR55","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jid.2020.05.115","volume":"141","author":"MS Garshick","year":"2021","unstructured":"Garshick, M. S. et al. Characterization of PCSK9 in the blood and skin of psoriasis. J. Invest. Dermatol. 141 (2), 308\u2013315 (2021).","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"72219_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12944-023-01901-4","volume":"22","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. Lipoprotein(a) is a new prognostic factor in patients with psoriasis and coronary artery disease: A retrospective cohort study. Lipids Health Dis. 22 (1), 141 (2023).","journal-title":"Lipids Health Dis."},{"issue":"6","key":"72219_CR57","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2165\/11319310-000000000-00000","volume":"11","author":"S Coimbra","year":"2010","unstructured":"Coimbra, S. et al. Psoriasis therapy and cardiovascular risk factors: A 12-week follow-up study. Am. J. Clin. Dermatol. 11 (6), 423\u2013432 (2010).","journal-title":"Am. J. Clin. Dermatol."},{"key":"72219_CR58","doi-asserted-by":"crossref","unstructured":"Zhang, F. et al. Annexin A6 polymorphism is associated with pro-atherogenic lipid profiles and with the downregulation of methotrexate on anti-atherogenic lipid profiles in psoriasis. J. Clin. Med. 11(23) (2022).","DOI":"10.3390\/jcm11237059"},{"issue":"3","key":"72219_CR59","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/art.22447","volume":"56","author":"N Sattar","year":"2007","unstructured":"Sattar, N. et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study. Arthritis Rheum. 56 (3), 831\u2013839 (2007).","journal-title":"Arthritis Rheum."},{"issue":"9","key":"72219_CR60","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1111\/jdv.19191","volume":"37","author":"A Gonzalez-Cantero","year":"2023","unstructured":"Gonzalez-Cantero, A. et al. Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Academy of Dermatology and Venerology. J. Eur. Acad. Dermatol. Venereol. 37 (9), 1697\u20131705 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"72219_CR62","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jid.2021.07.190","volume":"142","author":"MS Garshick","year":"2022","unstructured":"Garshick, M. S. et al. A randomized open-label clinical trial of lipid-lowering therapy in psoriasis to reduce vascular endothelial inflammation. J. Invest. Dermatol. 142 (6), 1749\u201352e4 (2022).","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"72219_CR63","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaad.2024.07.1511","volume":"91","author":"A Ormaza Vera","year":"2024","unstructured":"Ormaza Vera, A., Yap, A., Perkins-Holtsclaw, K. J., Van Voorhees, A. S. & Enos, C. W. Major adverse cardiovascular events are more frequent in psoriasis patients compared to controls, despite statin therapy: An observational retrospective cohort study. J. Am. Acad. Dermatol. 91 (6), 1254\u20131256 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"72219_CR64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","volume":"136","author":"JB Lerman","year":"2017","unstructured":"Lerman, J. B. et al. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation 136 (3), 263\u2013276 (2017).","journal-title":"Circulation"},{"key":"72219_CR65","doi-asserted-by":"publisher","first-page":"105485","DOI":"10.1016\/j.ebiom.2024.105485","volume":"111","author":"K Kridin","year":"2025","unstructured":"Kridin, K. et al. Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. EBioMedicine 111, 105485 (2025).","journal-title":"EBioMedicine"},{"key":"72219_CR66","doi-asserted-by":"crossref","unstructured":"Zoungas, S. et al. Atorvastatin, cardiovascular events, and disability-free survival in older adults. N. Engl. J. Med. (2026). Please give the citation in the same style as the others PMID: 42670961 DOI: 10.1056\/NEJMoa2607314","DOI":"10.1056\/NEJMoa2607314"},{"issue":"10","key":"72219_CR67","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.jid.2023.02.037","volume":"143","author":"S Piaserico","year":"2023","unstructured":"Piaserico, S. et al. Coronary microvascular dysfunction in asymptomatic patients with severe psoriasis. J. Invest. Dermatol. 143 (10), 1929\u201336e2 (2023).","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"72219_CR68","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jchf.2024.04.016","volume":"12","author":"A Tada","year":"2024","unstructured":"Tada, A. et al. Autoimmune disorders in heart failure with preserved ejection fraction. JACC Heart Fail. 12 (7), 1257\u20131269 (2024).","journal-title":"JACC Heart Fail."},{"issue":"3","key":"72219_CR69","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamadermatol.2021.4467","volume":"158","author":"JS Barbieri","year":"2022","unstructured":"Barbieri, J. S. et al. Analysis of specialist and patient perspectives on strategies to improve cardiovascular disease prevention among persons with psoriatic disease. JAMA Dermatol. 158 (3), 252\u2013259 (2022).","journal-title":"JAMA Dermatol."},{"issue":"4","key":"72219_CR70","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/24755303221101848","volume":"7","author":"AC Gustafson","year":"2022","unstructured":"Gustafson, A. C. et al. Specialist and patient perspectives on strategies to improve cardiovascular disease prevention among persons living with psoriatic disease. J. Psoriasis Psoriatic Arthritis 7 (4), 174\u2013186 (2022).","journal-title":"J. Psoriasis Psoriatic Arthritis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-72219-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-72219-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-72219-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:01:34Z","timestamp":1791104494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-72219-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72219"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-72219-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK declares having received consultancy honoraria from Almirall and lecture honoraria from Janssen-Cilag GmbH. KSK has received travel support from Almirall, Janssen Cilag GmbH and Eli Lilly. JW has received travel support from Alexion Pharma Germany GmbH and consultancy honoraria from CSL Vifor. The other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the Declaration of Helsinki. The study was approved by the ethics committee of Mainz (approval no. 2022\u201316565_1), and patients provided written and informed consent.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study (please see Ethics approval).","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30700"}}